Male breast cancer (MBC) is a poorly characterized disease because of its rarity. Clinical
management is based on results obtained from randomized trials conducted in women …

Breast cancer is the most common cancer form in women and it has been extensively
studied on the molecular level. Male breast cancer (MBC), on the other hand, is rare and has …

The incidence of male breast cancer (MBC) is rising; however, mortality due to MBC has not
changed, unlike female breast cancer. This lack of change is mostly attributable to a lack of …

Male breast cancer remains understudied despite evidence of rising incidence. Using a co-
ordinated multi-centre approach, we present the first large scale biomarker study to define …

Purpose: Male breast cancer is rare, and its genomic landscape has yet to be fully
characterized. Lacking studies in men, treatment of males with breast cancer is extrapolated …

Significant advances have been made in the diagnosis and treatment of female breast
cancer, resulting in a decline in incidence and a global improvement in clinical outcome …

Male breast cancer (MBC) is extremely rare and poorly characterized on the molecular level.
Using high-resolution genomic data, we aimed to characterize MBC by genomic imbalances …

Background and study design Male breast cancer (MBC) is a rare disease compared with
female BC and our current understanding regarding breast carcinogenesis in men has been …

Male breast cancer (MBC) is extremely rare and accounts for less than 1% of all breast
malignancies. Therefore, clinical management of MBC is currently guided by research on …

It has become customary to extrapolate from the results of treatment trials for female
breastcancer and apply them to males with the disease. In the absence of results from …